ASH 2021 Post-Conference Perspectives: Updates in Multiple Myeloma : Episode 1

Video

December 23, 2021

Upcoming Post-Conference Perspectives: ASH 2021

Author(s):

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Now Viewing

EP: 1.Upcoming Post-Conference Perspectives: ASH 2021

EP: 2.The MASTER Trial: Frontline Dara-KRd in Newly Diagnosed Multiple Myeloma

EP: 3.Frontline Use of Daratumumab-Based Regimens in Transplant-Ineligible MM

EP: 4.Rescue Isatuximab in Transplant-Ineligible, Treatment Naïve NDMM

EP: 5.Multiple Myeloma: Current Approaches to Frontline Therapy

EP: 6.2-Year Followup Data From the GRIFFIN Trial in Transplant-Ineligible NDMM

EP: 7.Novel Therapy for Multiple Myeloma: Future Directions in Care

EP: 8.How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Testing in multiple myeloma | Image credit: angellodeco - stock.adobe.com

June 12th 2025

DVRd Improves MRD Negativity, Maintains Quality of Life in Multiple Myeloma

Pearl Steinzor

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com

June 7th 2025

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

Jared Kaltwasser

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).

May 19th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

Laura Joszt, MA

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.